CD8A and neoplasm: In mice treated with NDV-αCTLA-4 or NDV-sPD-1, there was an increase in the number of CT26LacZ tumor-specific CD8+ cells compared to PBS-treated mice (p < 0.01 and p < 0.05, respectively), as well as compared to NDV-GFP-treated mice (p < 0.01 and p < 0.05, respectively; Figure 8B).